false 0001145604 0001145604 2024-10-02 2024-10-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 9, 2024 (October 2, 2024)

NIKA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

colorado  000-56234  90-0292940
(State or other jurisdiction of Nika Pharmaceuticals, Inc.) (Commission File Number) (IRS Employer Identification No.)

2269 Merrimack Valley Avenue
Henderson, NV 89044
(Address of principal executive offices) (Zip code)

(702)-326-3615
Registrant's telephone number, including area code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Section 4 - Matters Related to Accountants and Financial Statements

Item 4.01 Changes in Registrant’s Certifying Accountant.

On October 2, 2024, Nika Pharmaceuticals, Inc. made a discovery, which led it to consider that it is in the best interest not to continue its engagement of independent accountant OLAYINKA OYEBOLA & CO (Chartered Accountants). No services had been performed by OLAYINKA OYEBOLA & CO (Chartered Accountants) prior to the termination of the engagement on October 2, 2024.

On October 5, 2024, Nika Pharmaceuticals, Inc. engaged the firm of Boladale Lawal & Co (Chartered Accountants) to serve as the independent accountant to audit the company’s financial statements.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

23.1 Nika Pharmaceuticals Accountants) Inc. Dismissal Consent by OLAYINKA OYEBOLA & CO (Chartered Accountants)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

  NIKA PHARMACEUTICALS, INC.
   
Dated: October 9, 2024 By: /s/ Dimitar Slavchev Savov
    Dimitar Slavchev Savov
    Chief Executive Officer,
    Director


October 16, 2024

United States Securities and Exchange
Commission Office of the Chief Accountant
100 F Street, N.E.
Washington, D.C.
20549

Re: Nika Pharmaceuticals, Inc.

Dear Sirs/Madams,

We have read the statements under item 4.01 in Form 8-K dated October 9, 2024, of Nika Pharmaceuticals, Inc. to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm.

Regards,

Yours faithfully,
For: Olayinka Oyebola & Co


Yinka Oyebola FCA
Managing Partner/CEO

v3.24.3
Cover
Oct. 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 02, 2024
Entity File Number 000-56234
Entity Registrant Name NIKA PHARMACEUTICALS, INC.
Entity Central Index Key 0001145604
Entity Tax Identification Number 90-0292940
Entity Incorporation, State or Country Code CO
Entity Address, Address Line One 2269 Merrimack Valley Avenue
Entity Address, City or Town Henderson
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89044
City Area Code 702
Local Phone Number 326-3615
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Nika Pharmaceuticals (PK) (USOTC:NIKA)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Nika Pharmaceuticals (PK) Charts.
Nika Pharmaceuticals (PK) (USOTC:NIKA)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Nika Pharmaceuticals (PK) Charts.